title: Serum testosterone kinetics after brachytherapy for clinically localized prostate cancer.
abstract: OBJECTIVE
  To evaluate temporal changes in testosterone after prostate brachytherapy and investigate the potential impact of these changes on response to treatment.
  
  
  METHODS
  Between January 2008 and March 2009, 221 consecutive patients underwent Pd-103 brachytherapy without androgen deprivation for clinically localized prostate cancer. Prebrachytherapy prostate-specific antigen (PSA) and serum testosterone were obtained for each patient. Repeat levels were obtained 3 months after brachytherapy and at least every 6 months thereafter. Multiple clinical, treatment, and dosimetric parameters were evaluated to determine an association with temporal testosterone changes. In addition, analysis was conducted to determine if there was an association between testosterone changes and treatment outcomes or the occurrence of a PSA spike.
  
  
  RESULTS
  There was no significant difference in serum testosterone over time after implant (p = 0.57). 29% of men experienced an increase ≥ 25%, 23% of men experienced a decrease ≥ 25%, and the remaining 48% of men had no notable change in testosterone over time. There was no difference in testosterone trends between men who received external beam radiotherapy and those who did not (p = 0.12). On multivariate analysis, preimplant testosterone was the only variable that consistently predicted for changes in testosterone over time. Men with higher than average testosterone tended to experience drop in testosterone (p < 0.001), whereas men with average or below average baseline testosterone had no significant change. There was no association between men who experienced PSA spike and testosterone temporal trends (p = 0.50) nor between initial PSA response and testosterone trends (p = 0.21).
  
  
  CONCLUSIONS
  Prostate brachytherapy does not appear to impact serum testosterone over time. Changes in serum testosterone do not appear to be associated with PSA spike phenomena nor with initial PSA response to treatment; therefore, PSA response does not seem related to temporal testosterone changes.
authors.affiliation: Western Radiation Oncology, Mountain View, CA, USA.
authors.forename: Al V
authors.initials: AV
authors.lastname: Taira
authors.forename: Gregory S
authors.initials: GS
authors.lastname: Merrick
authors.forename: Robert W
authors.initials: RW
authors.lastname: Galbreath
authors.forename: Wayne M
authors.initials: WM
authors.lastname: Butler
authors.forename: Jonathan H
authors.initials: JH
authors.lastname: Lief
authors.forename: Zachariah A
authors.initials: ZA
authors.lastname: Allen
authors.forename: Kent E
authors.initials: KE
authors.lastname: Wallner
mesh_terms: D000704:Analysis of Variance; D001918:Brachytherapy / Q000379:methods*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010165:Palladium / Q000627:therapeutic use; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood* / Q000532:radiotherapy*; D011868:Radioisotopes / Q000627:therapeutic use; D013739:Testosterone / Q000097:blood*; D013997:Time Factors
chemical_list: D011868:Radioisotopes; D013739:Testosterone; D010165:Palladium; D017430:Prostate-Specific Antigen